ASX Release

4 November 2026

DR NICOLE VAN DER WEERDEN APPOINTED CEO

The Company has appointed Dr Nicole Van Der Weerden as Acting Chief Executive Officer effective today.

"Arovella is now a clinical stage company and I am proud to be leading it at this pivotal time as we deliver on our objectives. I have great confidence in our platform, our strategy and the team behind it, and I am excited about what we will achieve together. I sincerely thank the Board and the entire Arovella team for their support and commitment" said Dr. Van Der Weerden.

Arovella's Chairman, Mr David Williams, said: "I have worked very closely with Nicole now for six months and I am very happy with her CEO skills, knowledge of the science, but most of all her willingness to work with me on Business Development and at the pace I like to work. I am very optimistic about what we can do together in the short term. Nicole is very impressive and also has an impressive team with her. The Board and I will provide her with any support she requires. I am very much looking forward to working together. The Board is particularly happy with the results of the last 6 months being the successful manufacture of product for dosing, the signing of 6 hospitals for our trial, the dosing of the first patient and the great animal data in tumours"

Dr. Van Der Weerden's salary will be $401,700 plus superannuation and will be eligible for Short Term Incentive (STI) and Long Term Incentive (LTI) bonuses of up to 40% of the salary paid for each incentive. There are no other changes made to employment terms.

Biography – Dr Nicole Van Der Weerden



Dr Van Der Weerden is an experienced biotechnology executive who joined Arovella in 2023 as Chief Operating Officer. Prior to Arovella, she spent over 18 years at Hexima Ltd in a range of roles including COO, CEO and Non-executive director. There, she was responsible for advancing Hexima's lead drug candidate through pre-clinical and clinical development. Dr. Van Der Weerden has a PhD in Biochemistry and MBA from Melbourne Business School and is Graduate of the Australian Institute of Company Directors.

Release authorised by the Arovella Limited Board of Directors.

FURTHER INFORMATION

Dr Nicole Van Der Weerden
Chief Executive Officer
E nvanderweerden@arovella.com
M +61 407 039 983

David Williams
Chairman
E dwilliams@kidder.com.au
M + 61 414 383 593

About Arovella Therapeutics Ltd

Arovella Therapeutics Ltd (ASX: ALA) is focused on developing its invariant natural killer T (iNKT) cell therapy platform licensed from Imperial College London to treat blood cancers, solid tumours, and autoimmune disease. Arovella's lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. iNKT cells also contain an invariant T cell receptor (iTCR) that targets glycolipid bound CD1d, another antigen found on the surface of several cancer types. ALA-101 has had its Investigational New Drug application (IND) accepted by the US FDA and is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. Arovella is also expanding into solid tumour treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Arovella will also incorporate its IL-12-TM technology into its solid tumour programs.

For more information, visit www.arovella.com